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Enzymatic and binding effects of atrial natriuretic factor in glomeruli
and nephrons. Atrial natriuretic factor (ANF) has been suggested to
exert a tubular effect on the mammalian nephron, perhaps in part by
interacting with other hormones. In the present study, the effect of
ANF was examined on glomeruli (Gm) and different renal tubule
segments including medullary (MAL) and cortical thick ascending limb
(CAL) and cortical (CCT), outer medullary (OMCT) and inner medul-
lary collecting tubules (IMCT). This effect of ANF was assessed by
alteration in adenylate cyclase and cGMP in the various nephron
segments in the presence and absence of arginine vasopressin (AVP),
parathyroid hormone (PTH) and calcitonin (SCT). An effect of ANF
(10—8 M) was not demonstrated on adenylate cyclase (fmol cAMP
formed/30 min/g protein) in Gm, CAL, MAL, CCT, OMCT or IMCT.
Nor did ANF (10— 8 M) interfere with the effect of PTH (5 lU/mi) on the
Gm (PTH 35.1 3.7 vs. PTH + ANF 32.5 1.8, NS), CAL (PTH 50.5
10.9 vs. PTH + ANF 46.2 1.4, NS) or AVP (l08 M) on the CCT
(AVP 40.8 6.6 vs. AVP + ANF 33.0 3.1, NS), OMCT (AVP 56.0
11.8 vs. AVP + ANF 42.1 6.7, NS), IMCT (AVP 66.5 4.6 vs.
AVP + ANF 53.5 7.0, NS)or MAL(AVP 15.5 1.6 vs. AVP + ANF
14.0 2.6, NS). ANF also did not affect SCT (1.5 x l08 M)-induced
adenylate cyclase on CCT (SCT 69.8 11.3 vs. SCT + ANF 79.9 7.2,
NS). ANF (l0— M), however, significantly increased cGMP in the Gm
(6.4 1.7 to 121.3 32.4 fmol/tg protein, P < 0.001) and IMCT (0.63
0.16 to 1.46 0.29 fmol/tg protein, P < 0.05). However, no effect of
ANF on cGMP was observed in the CAL, CCT, OMCT, and MAL even
at iO M ANF. PTH (5 lU/mi) did not alter either basal or ANF-
stimulated cGMP in the Gm. Also, specific ANF binding was studied in
the microdissected IMCT. Kd was 6.08 x lO M and Bmax was 8.07 x
M. These results suggest that ANF does not exert a direct effect
on the cellular action of AVP, PTH or SCT, but may exert a significant
physiological role in the Gm and IMCT by increasing cGMP.
Atrial natriuretic factor (ANF) has been demonstrated to be
released from myocardiocytes [1], and has been reported to
exert potent natriuretic and diuretic effects in several species
[1—61. Although it is generally accepted that ANF increases the
renal excretion of sodium and water, there have been con-
flicting reports about the mechanism of action and target sites of
ANF action in the kidney. In studies using renal tissue plasma
membranes, specific binding of ANF was demonstrated in
rabbit and rat renal cortical plasma membranes [7, 81 and in
LLC-PK1 cells [7]. The major ANF binding in the renal cortex
appears to be in the glomeruli [9]. Moreover, specific ANF
binding has been shown in the isolated rat and human glomeruli
and in cultured rat glomerular mesangial cells [9]. Autoradiog-
raphy studies have indicated that ANF receptors were distrib-
uted mainly in glomeruli in cortex [10, 11] with low amounts of
receptors occurring in proximal tubules [11] and in inner
medullary collecting tubules (IMCT) [10, 11].
Although it has been suggested that the natriuretic effect of
ANF is due primarily to an increase in glomerular filtration and
filtered sodium load, a specific inhibition of sodium reabsorp-
tion in the collecting tubule has been proposed [4]. In this
regard, an effect of ANF to decrease sodium permeability of the
IMCT has been demonstrated in studies by Zeidel et al [121.
Recently it has also been reported that ANF inhibited the
hydraulic conductivity response to arginine vasopressin (AVP)
but not to either cAMP or forskolin in the microperfused rabbit
cortical collecting tubules (CCT) [13]. This finding thus suggests
a potential effect of ANF on the action of AVP in the mamma-
lian distal nephron. ANF also has been shown to inhibit
AVP-stimulated cAMP production as well as stimulate cGMP in
the cultured rat inner medullary cells [14]. A physiological role
for cGMP in the action of ANF in the kidney has been
suggested since ANF was shown to increase cGMP levels in
cultured or dissected rat inner medullary cells [14—16], rat,
rabbit, and human glomeruli [8, 17, 18], and in cultured rat
glomerular mesangial cells [9]. Taken together, these studies
suggest that the natriuretic and diuretic effect of ANF might be
due to a direct action of ANF on renal tubules as well as a
potential interaction with other hormones, perhaps involving
cGMP generation. The present study was therefore undertaken
to examine the effect of ANF and its interaction with AVP,
PTH and calcitonin on the stimulation of adenylate cyclase and
cGMP production along the rat nephron, including the glomer-
uli, proximal tubule, cortical (CAL) and medullary thick as-
cending limb of Henle's Loop (MAL), collecting tubules of
cortex (CCT), outer (OMCT) and inner medullary (IMCT), and
ANF binding to IMCT.
Methods
Synthetic ANF (Ile-ANF-26) was from Dr. Edward Blame
(Merck Sharp and Dohme, West Point, Pennsylvania, USA).
This peptide has been shown to have properties identical to
native ANF of a low molecular weight [19].
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Microdissection of tubules and glomeruli
The rats (200 to 250 g body wt) were lightly anesthetized with
pentobarbital (3 mg/l00 g body wt) and the left kidney was
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perfused [20—22] with 10 ml of collagenase medium [137 m
NaC1, 5 mivi KC1, 0.8 mrvi MgSO4, 0.8 mM Na2HOP4, 1 mM
MgC12, 1 mri CaCl2, 10 ifiM Tris, pH 7.4, 120 to 200 U/mi
coliagenase (Millipore Corp., Greenhold, New Jersey, USA), 1
mg/mi hyaluronidase (Sigma Chemical Co., St. Louis, Mis-
souri, USA), and 1 mg/mi bovine serum albumin with 20 U/mi
heparin] at an infusion rate of 1 mi/mm. The cortical, outer
meduliary and inner medullary (papillary) tissue was dissected
and sliced into thin strips with direction from cortex to papillary
tip. Then the pieces were incubated in an aerated collagenase
medium for 60 minutes for papillary tissue and 30 minutes for
cortical and medullary tissues at 35°C. After incubation the
tissues were washed with cold microdissection medium (same
as the collagenase medium except 0.25 mri CaC12 and no
collagenase, hyaluronidase, and bovine serum albumin) and
kept on ice while microdissection was performed. CCT, OMCT
and IMCT, and CAL and MAL and glomeruli were dissected
under a stereomicroscope using thin needles. Dissected glomer-
uli (10 glomeruli for each assay) and tubules (1.5 to 2.0 mm for
each assay) were transferred to a concave bacteriological slide
by aspiration of tubules in a small droplet of microdissection
medium. For assays of adenylate cyclase, lengths of the tubules
were measured using a microscope with computerized planim-
eter (Carl Zeiss, Oberkochen, FRG). Tubules then were dis-
rupted by hypoosmotic shock with freezing and thawing. After
the microdissection, the medium was aspirated and 0.5 p1 of
hypoosmotic medium (1 mrvi MgCl2, 0.25 mvt EDTA, 0.1%
bovine serum albumin, and 1 m Tris, pH 7.4) was added under
the microscope; the samples were then immediately frozen by
placing them on a block of dry ice. The frozen tubules were
thawed once and refrozen, then kept at —80°C until assayed.
The basal and hormone stimulated activities of adenylate cy-
clase were stable at least for five days at —80°C.
Assays of adenylate cyclase activity
The activity of adenylate cyclase was measured according to
a modification [20—22] of the method of Morel, Chabardes and
Imbert-Teboul [23]. Briefly, slides with tubules (1.5 to 2 mm
total tubule length per sample) were incubated at 37°C for 30
minutes in a final volume of 5.5 p1 containing 0.25 m alpha-
32PATP (3 to 4 x 106 cpm/sample), 1 m'vi cAMP, 3.8 mM
MgCL2, 0.25 m EDTA, 20 mtvi creatine phosphate (Calbio-
chem, San Diego, California), 200 U/ml creatine phosphokinase
(Calbiochem), and 100 mi Tris, pH 7.4, with or without
addition of ANF or hormone, or ANF + hormone [AVP,
Bachem, Torrance, California, USA; caicitonin, Calbiochem;
parathyroid (PTH), Sigma]. The reaction was stopped by addi-
tion of 150 p1 stopping solution (3.3 mivi ATP, 5 m'vi cAMP, 50
mM Tris HC1, pH 7.4, and 3H-cAMP containing 1 X i04 cpm/
sample to determine recovery). Produced 32P-cAMP was sepa-
rated according to the method of Salomon [241 using Dowex
50-x4, 200 to 400 mesh (Biorad, Richmond, California, USA),
and albumin oxide columns (ICN, Cleveland, Ohio, USA).
Most of the enzyme activity was expressed as fmol cAMP
produced/min/g protein for tubules and fmol cAMP produced/
mi&g of protein for glomeruli.
Determination of in situ cGMP
The cGMP content was determined by radioimmunoassay
and the cells were treated as in the cAMP measurement [20-221.
The microdissection medium was aspirated off and 2.5 p1 of
modified Krebs-Ringerbuffer(140 m'vi NaC1, 5mM KC1, 1,2mM
MgSO4, 10 m glucose, 0.8 mivi CaC12, 10 m sodium acetate,
2 m'vi NaH2PO4), 0.2 mii MIX (l-methyl-3-isobutylxanthine),
and 20 mri Tris-HC1, pH 7.4, was added without (basal) or with
ANF (Ile-ANF-26) or other hormones. The samples were
covered with vaseline-coated concave slides and were incu-
bated at 30°C for 10 minutes. The incubation was stopped by
freezing on dry ice, then the frozen samples were transferred to
12 x 75 glass tubes. One hundred microliters of buffer of 50 mM
sodium acetate, pH 6.2, was added and boiled for three min-
utes. The samples were stored at —20°C until assayed. Follow-
ing acetylation of the experimental samples and standard,
cGMP was determined by radioimmunoassay using cGMP [125J]
tracer (RIA kit from Dupont Co., New England Nuclear Prod.,
Billerica, Massachusetts, USA). In all experiments microdis-
section and assay of basal activities or with hormone was
performed on the same tissue. The assays were performed in
four replications. The standard curves ranged from 1 to 100
fmol/tube, the coefficient of determination was 0.988 to 0.997
and the cGMP concentration of samples was not lower than 1
fmol/assay. The cGMP content was expressed as fmolIg
protein of glomeruli or tubules. With this procedure, recovery
of cGMP applied on blank slides was 96 to 99%. Therefore,
3H-cGMP was not added to each sample for recovery.
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Fig. 1. Effect of ANF on adenylate cyclase of rat glomeruli. Each bar
represents mean SEM. Symbols are: (0) basal, (•) ANF iO M, ()
ANF 10-8 M, () ANF 10 M. N = 5, number of rats.
30
10
Kim el al: ANF interaction with AVP and other hormones 801
Fig. 2. Effect of ANF on A VP-stimulated
adenylate cyclase of rat cortical collecting
tubule (CCT), out er (OMCT) and inner
medullary collecting tubule (IMCT), and
medullary thick ascending limb (MAL). Each
bar represents mean SEM. Symbols are: ()
basal, () ANF 10-8 M, () AVP 10-8 M,() ANF + AVP 108 M; < 0.02 vs.
basal, 88P < 0.05 vs. basal, + P < 0.001 vs.
basal (basal vs. AVP). N = number of rats.
ANF binding to isolated JMCT
125! ANF binding to IMCT was performed by a modified
method of Napier et a! [91. 34125JJ iodotyrosyl28ANF (specific
activity 1950 Ci/mmol) was purchased from Amersham (Ar-
lington Heights, Illinois, USA). The binding assay was per-
formed in total volume of 50 sl in a microcentrifuge tube
containing dissected IMCT (total length 20 mm), and Tris-BSA
buffer cOntaining 10 mtvi MgCl2, 0.1% bacitracin, 0.2% BSA, 50
mM Tris-HCL, pH 7.4, 1 x 10b0 M '251-ANF and various
concentrations of unlabeled ANF (5 x iO° M, I X i0 M, 5
X iQ— M, 1 X iO M). The reaction mixture was incubated at
4°C for 30 minutes, and the reaction was stopped by adding 950
jl cold Tris-BSA buffer. The tubes were immediately centri-
fuged for 10 minutes at 15,000 x g. After the centrifugation, the
supernatant was removed and the pellet was carefully washed
twice with 1 ml cold Tris-BSA buffer, The time course study
showed that the binding equilibration was reached at 15 minutes
at 30°C and maintained up to 40 minutes. The nonspecific
binding was determined in the presence of 1 x 106 M unlabeled
ANF. Kd and Bmax were calculated using an equilibrium
binding data analysis of the Radioligand Binding Analysis
Programs by G.A. McPherson (Elsevier-BIOSOFT). This com-
puter program was designed to analyze the radioligand binding
studies by Scatchard plot. The equation is [B] = Bmax — Kd
[Bj/[L], where [B] is bound; [LI, free; Bmax, maximal number of
receptor; and Kd, dissociation constant. Protein was deter-
mined by a modified method from Lowry et a! [251. With this
micromethod, proteins ranged in 0.2 to 1.0 g can be measured
[20—221.
Results
Adenylate cyclase determinations
ANF alone at concentrations of iO to iO M did not show
any significant effect on adenylate cyclase activities in the
isolated glomeruli (Fig. 1), although there were slight but
insignificant increases in adenylate cyclase activities by 10—8
and iO M ANF. To determine whether ANF exerted any
effect on the AVP-stimulated adenylate cyclase, the effect of
iO M ANF on a submaximal stimulatory concentration of
l0 M AVP was examined on the adenylate cyclase of AVP-
sensitive renal nephron segments. As shown in Figure 2, ANF
alone at iO M did not affect the basal activities of adenylate
cyclase in the CCT, OMCT, IMCT, and MAL, and also showed
no effect on the AVP-stimulated adenylate cyclase in these
renal tubules. In Figure 3 is shown the effect of i0 M ANF on
the AVP dose-responsive stimulation of adenylate cyclase in
IMCT. There was also no significant effect of ANF on the AVP
stimulation of adenylate cyclase in these studies.
In glomeruli (Fig. 4), 5 IU/ml of PTH significantly increased
adenylate cyclase (basal 20.6 3.5 vs. 5 IU/ml PTH 35.1 3.7
fmol cAMP formed/min/g, P < 0.02) and 10—8 M ANF did not
affect this PTH-stimulated adenylate cyclase. The same pattern
of results was shown in the CAL (Fig. 4); l0 M ANF did not
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Fig. 3. Effect of ANF on A VP dose-responsive adenylate cyclase of rat
IMCT. Each bar represents mean SEM. Symbols are: (• •)
control, (O--O) + ANF l0 M. N = 4. number of rats.
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Fig. 4. Effect of ANF on PTH-stimulated
adenylate cyclase in rat glomeruli and cortical
thick ascending limb (CAL). Each bar
represents mean SEM. N = number of rats.
Effect of ANF on cGMP
ANF significantly increased cGMP levels in the isolated rat
glomeruli (basal 6.1 3.1 vs. 10_8 M ANF 119.4 38.9, P <
0.01, l0— M ANF 121.3 37.4, P <0.01; Fig. 6). As shown in
Figure 7, 5 lU/mi PTH showed no effect on either basal cGMP
levels or ANF-stimulated cGMP concentrations in the isolated
glomeruli. The effect of ANF on the cGMP concentrations was
studied in several nephron segments, including the proximal
tubule (P x T), CAL, MAL, CCT, OMCT, and IMCT. These
results are shown in Figure 8. ANF (l0— M) significantly
increased cGMP levels only in the IMCT (0.63 0.16 to 1.46
0:29 fmol/JLg protein, P < 0.05) and this increase was consistent
in every rat. There were no significant increases in cGMP
induced by ANF in any of the other renal tubules. The basal
concentrations of cGMP were higher in the CCT as compared to
other renal tubules.
125j ANF binding to IMCT
Fig. 5. Effect of ANF on calcitonin-stimulated adenylate cyclase of rat
CCT. Each bar represents mean SEM. N = 4, number of rats.
show any effect on either basal activities or PTH-stimulated
adenylate cyclase.
Calcitonin is known to stimulate adenylate cyclase in CCT.
As shown in Figure 5, 10—8 M ANF slightly but insignificantly
increased the calcitonin-stimulated adenylate cyclase (1.5 x
10s M SCT 69.8 11.3, SCT + 10_8 M ANF 79.9 7.2 fmol
cAMP formed/min/rg protein, NS).
125j ANF binding was studied only in the microdissected
IMCT, since IMCT was the renal tubule in which ANF stimu-
lated cGMP. In Figure 9 is shown the Scatchard plot of ANF
binding to IMCT. It suggests one homogeneous receptor pop-
ulation of ANF in rat IMCT. Kd was 6.08 X i0 M and Bmax
was 8.08 x 10_il M. Nonspecific binding was 23 to 28%.
Discussion
There is little doubt that the atrial natriuretic peptides in-
crease urine flow and sodium excretion in a number of different
species [1—6]. The exact mechanism for these effects, however,
remains a matter of some debate. The glomerular binding and
stimulation of cGMP production is the most profound effect of
ANF in the kidney, and ANF has been shown to increase
glomerular filtration rate (GFR) significantly in several studies
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[101 have also recently shown that ANF binds to rat inner
medullary rich cells separated by gradient centrifugation, show-
ing a Kd of 2.1 x l0_8 M. The ANF binding results in the
present study, however, revealed an ANF affinity with a Kd of
6.08 x lO M. Differences in the Kd for ANF binding might be
due to the two different preparations of tubular cells studied.
The receptor number for ANF on IMCT in our study as
assessed by Bmax was 8.07 X lO M or 1900 fmol/mg protein.
Another possible mechanism of action of ANF in the mam-
malian nephron has been suggested by results which indicated
an effect of ANF to interfere with other hormones, particularly
AVP, which stimulate the adenylate cyclase-cAMP system. In
a recent study in the dog, ANF inhibited adenylate cyclase in
glomeruli, loops of Henle and collecting tubules [29]. ANF has
also been shown to inhibit AVP-induced water flux in the rabbit
cortical collecting tubules [13]. On the other hand, in other
studies, ANF did not inhibit AVP-stimulated cAMP in cultured
rabbit CCT [301, or dissected CCT and OMCT from the rat or
rabbit [18, 31]. ANF has also not been found to alter transmural
voltage or the lumen to bath chloride fluxes in perfused loops of
Henle [32].
A comprehensive investigation was therefore performed in
the present study in search for an interaction between ANF and
hormones whose action involves the adenylate cyclase-cAMP
system. Several hormones were used and different segments of
the rat nephron were studied; the results were rather clear.
There was no evidence of ANF inhibition of the effect of
calcitonin, PTH or AVP to stimulate adenylate cyclase in
isolated rat nephron segments. It should be emphasized, how-
ever, that these results on adenylate cyclase activity were
obtained in permeablized tubular cells, and may not be compa-
rable to studies performed in membrane preparations as well-
preserved living tubules which measured cAMP generation
from endogenous ATP rather than adenylate cyclase activity. In
ri
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Fig. 7. Effect of PTH and ANF on glomerular cGMP. Each bar
represents mean SEM. N = 4, number of rats.
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Fig. 6. Effect of ANF on cGMP of rat glomeruli. Each bar represents
mean SEM. N = 5, number of rats; *P < 0.01.
[3, 26, 27]. However, against the role of GFR as the primary
modulator of the natriuretic and diuretic effect of ANF is the
finding of several investigators that ANF causes a diuresis and
natriuresis in spite of any detectable increases in GFR 16, 28].
Recent attention has therefore been focused on potential
effects of ANF on the distal nephron. The potential role of the
distal nephron in the natriuretic and diuretic response to ANF
has been proposed for several reasons. First of all, in addition
to the renal cortical binding of ANF, which occurs primarily in
the glomerulus, ANF binding has been observed by autoradi-
ography in the inner medullary or papillary region of the kidney
[10, 11]. Such membrane binding, however, could occur on
interstitial cells, vasculature or tubular epithelium. In fact,
Ballerman et al [9] initially suggested that a vascular effect of
ANF in the papilla increased the hydrostatic driving force in the
vasa recti, a consequence that could result in the passive
movement of sodium from the interstitium into the collecting
duct. The same group has, however, now shown a direct effect
of ANF to decrease ouabain-sensitive oxygen consumption of
rabbit inner medullary collecting duct cells in suspension [12].
On the basis of these studies, an effect of ANF to decrease
sodium entry across the IMCT has been proposed. Such a
direct effect of ANF on sodium transport in the rat inner
medullary collecting duct is quite compatible with the present
findings that ANF both binds to IMCT and also significantly
stimulates cGMP production in the same segment. Koseki et al
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Fig. 8. Effect of ANF on cGMP in the rat
proximal tubules (PxT), CAL, MAL, CCT,
OMCT, and IMCT. Each bar represents mean
SEM. N = number of rats. Symbols are (LI)
basal, (E:) ANF lO M.
U-
0.0 15
0.010
0.005
0.000
4 6
ANF bound (x 10 17M)
Fig. 9. Scatchard plot of 125j ANF binding to rat IMCT. Each point
is the mean of three experiments, and each point of each experiment
is a mean of duplicate. Nonspecific binding was 23 to 28%. Kd 6.08 x
lO M; Bmx 8.07 x 10 M.
this regard, a previous report using an alpha-2-adrenergic
agonist showed no effects on adenylate cyclase response to
AVP, but inhibition of cAMP stimulation by AVP was demon-
strated in rat OMCT [33]. However, other studies [16, 18, 31]
with cAMP measurements in intact nephron segments reported
no effect of ANF on AVP-stimulated cAMP accumulation.
In the present investigation, ANF was found to bind to the
IMCT of the rat, the only site in which ANF stimulated cGMP
production in the nephron. These findings are consonant with
the results of a recent preliminary micropuncture study in the
rat in which an effect of ANF to inhibit tubular sodium
reabsorption in the collecting tubule was demonstrated [341.
Whether cGMP is the secondary messenger of such an effect of
ANF in the collecting tubule or a pan passu event, however,
must await further study. In this regard, it is interesting that
ANF analogues which do not stimulate cGMP production in
collecting duct cells are still modestly natriuretic in vivo (J.
Lewicki, personal communication).
In summary, ANF was shown not to interfere with hormones
which stimulate the adenylate cyclase-cAMP system including
AVP, PTH and calcitonin. Stimulation of cGMP production by
ANF, however, was observed not only to occur in the glomer-
ulus but also in the IMCT of the rat, both sites of ANF binding.
The IMCT may therefore be the major site of ANF action in the
rat distal nephron.
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